Funding round · Biotech
Omnio raised approximately €4.3m in May 2025
Existing shareholders backed manufacturing and preclinical development of the company’s wound-healing therapy.
Omnio announced approximately €4.3 million in financing on 20 May 2025, primarily from existing shareholders. The Swedish biotech was developing a plasminogen-based therapy for chronic wounds, initially diabetic foot ulcers.
The company said the funding would support completion of its GMP manufacturing process, preclinical regulatory studies and expansion of its regulatory and manufacturing teams. Omnio later announced a separate €2.9 million financing in October 2026.
Use of funds
Complete GMP manufacturing
Conduct preclinical regulatory studies
Expand regulatory and manufacturing teams
Funding history
Funding round · This round~€4.3M